Tanabe Pharma America, Inc.
Clinical trials sponsored by Tanabe Pharma America, Inc., explained in plain language.
-
ALS drug trial halted: oral Edaravone's promise unfulfilled
Disease control TerminatedThis study tested an oral form of edaravone in 384 adults with ALS to see if it could slow the disease's progression over 48 weeks. Participants were randomly assigned to different dosing schedules. The trial was terminated early, and results are not yet available.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
ALS drug edaravone put to the test in extended trial
Disease control TerminatedThis study looked at whether taking oral edaravone in two different dosing schedules can help slow the worsening of ALS, a nerve disease that weakens muscles over time. About 200 people who had already been in an earlier edaravone study took the drug for up to 48 more weeks. The …
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Early-Stage drug test in healthy people halted
Knowledge-focused TerminatedThis early-phase study tested the safety and how the body processes a new drug called MT-6345 in 52 healthy adults. The goal was to check for side effects and measure drug levels in the blood. The study was terminated early, so results are limited. No treatment was given for any …
Phase: PHASE1 • Sponsor: Tanabe Pharma America, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC